ELISA/assay

KRIBIOLISA™ Anti-Palivizumab ELISA (SYNAGIS)

KBI2080

1 x 96 wells

1040 USD

KRIBIOLISA™ Anti-Palivizumab ELISA (SYNAGIS)

ELISA

1 x 96 wells

1040 USD

Enzyme Immunoassay for quantitative detection of anti-Palivizumab antibodies in serum and plasma. About the kit: - Uses anti-idiotypic antibodies sourced from our vendor partner in the US, which ensures higher specificity, and low cross reactivity. - Recovery rates are between 85 - 115% - Ready to use with a standard protocol with break-apart pre-coated wells - Validated as per US FDA guidelines for Bioassays - Optimized for matrix effects to ensure higher sensitivity. - Shelf life: 1 year The method employs enzyme linked immunoassay technique. Standard or samples are pipetted into microwells pre-coated with the drug and anti-drug antibodies present in the sample and standards are bound by the drug. In the second step, HRP conjugate is pipetted and incubated. Free HRP conjugate will be removed by washing. Addition of TMB substrate will develop blue color and and reaction is stopped by addition of stop solution. Colour of the solution turns yellow. Intensity of yellow colour in wells is directly proportional to the concentration of anti-drug antibodies present in Standard or sample. Absorbance is measured at 450 nm.

Human

Palivizumab is a new anti-RSV monoclonal antibody product indicated for the prevention of serious lower respiratory tract disease caused by RSV in pediatric patients at high risk of developing RSV disease ("Synagis," 1998). Palivizumab was evaluated in a single, large clinical trial (IMpact) Anti-Palivizumab ELISA for the quantitative estimation of antibodies to Palivizumab in human serum and plasma. Ready to Use Anti Synagis Antibody Assay.

This ELISA kit comes with a pre-coated plate, concentrated or lyophilized standards, wash solution, subtrate, stop solution and all the required diluents. For the exact contents of the kit, please refer to the datasheet / IFU.

2-8 Deg C

10 ng/ml - 640 ng/ml

8.75 ng/ml

The method employs the quantitative sandwich enzyme immunoassay technique. Palivizumab is pre-coated onto microwells. Samples and standards are pipetted into microwells and antibodies to Palivizumab present in the sample are bound by the capture antibody. Then, a HRP (horseradish peroxidase) conjugated Palivizumab is pipetted and incubated. After washing microwells in order to remove any nonspecific binding, the ready to use substrate solution (TMB) is added to microwells and color develops proportionally to the amount of Anti-Palivizumab antibodies in the sample. Color development is then stopped by addition of stop solution. Absorbance is measured at 450 nm.

Anti-Palivizumab Antibodies

RUO

2-8 degrees C